Indian equities are poised for a constructive phase, with strategists anticipating earnings acceleration and a potential revival in foreign investor interest. While near-term earnings surprises are limited, FY27 is projected to see significant growth. Pharma is favored over IT, with selective opportunities in midcaps and other sectors.
Laurus Labs shares rally over 4% as Q1FY27 profit jumps 126% on strong CDMO growth
Laurus Labs reported a strong June-quarter performance, with net profit more than doubling and revenue rising 29% year-on-year, driven by robust growth in its CDMO